Regulatory FDA clears Orca’s cell therapy Tregzi for GvHD PharmaphorumOrca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.HematologyRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) Pharmaphorum Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca Wins CHMP Opinion for CLL Across All LinesNext: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026